Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: Business Wire
Clinical data builds upon body of evidence suggesting EXS-21546 is a highly potent and selective A2AR antagonist with low CNS exposureExscientia anticipates initiating Phase 1b/2 in patients with high adenosine signature cancers in second half of 2022Ongoing translational work to establish predictive biomarker to enable targeting of patients most likely to benefit from EXS-21546 OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist ??co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; Nasdaq: EVO). Topline data from this healthy volunteer study confirmed Exscientia’s target product profile design, including potency, high receptor selectivity and expected low brain exposure with no CNS adverse events reported, supporting advancement of EXS-21546 to a Phase 1b/
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the FirmAccesswire
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, and Akero and Encourages Investors to Contact the FirmGlobeNewswire
- Levi & Korsinsky Reminds Exscientia plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 – EXAIAccesswire
- ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Exscientia plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAIGlobeNewswire
- June 25, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - EXAIAccesswire
EXAI
Earnings
- 3/21/24 - Beat
EXAI
Sec Filings
- 4/24/24 - Form 144
- 4/22/24 - Form 6-K
- 4/8/24 - Form 144
- EXAI's page on the SEC website